A0817 Consistent efficacy of durable response in BCG relapse, refractory and unresponsive disease in a pre-determined subgroup analysis of ANKTIVA (NAI) plus BCG in BCGUnresponsive NMIBC CIS with or without Ta/T1 papillary disease

European Urology 2026

View at publisher

Authors: S. Chang, Karim Chamie, M. Huang, B. Brown, S. Reddy, Patrick Soon‐Shiong

DOI: 10.1016/s0302-2838(26)00863-8

Cited by: 0

Fields of Study & Subjects

Bladder and Urothelial Cancer Treatments Urinary Bladder and Prostate Research Urinary and Genital Oncology Studies